Active Research Protocols
- 09-C-0235 – A Phase 2, Open Label Trial of Dacomitinib (PF-00299804) in Selected Patients with Advanced Adenocarcinoma of the Lung
- 10-C-0071 – Phase 2, Open-Label Arm Study of the Efficacy and Safety of PF-02341066 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring a Translocation or Inversion Involving the Anaplastic Lymphoma Kinase (ALK) Gene Locus
- 10-C-0178 – A Phase 1/2 Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children with Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma
- 11-C-0250 – A Phase 1, Open-Label, Dose Escalation Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Combined Oral C-Met/ALK Inhibitor (PF-02341066) and Pan-Her Inhibitor (PF-0299804) in Patients with Advanced Non-Small Cell Lung Cancer
NOTE: PDF documents require the freeAdobe Reader.
This page was last updated: January 24, 2014